Research Reactor supplying radioisotope for new cancer drug
MU News Bureau
"I am delighted that MURR's research scientists have played such an integral role in promoting the merits of Lu-177 and for the ultimate success achieved by Lutathera," said David Robertson, director of research for MURR.
"Research and discoveries made at MURR and across campus will continue to improve the health and lives of citizens of Missouri, the nation and the world" said Mark McIntosh, vice president for research and economic development at the UM System and vice chancellor for research, graduate studies and economic development at MU. "Being the nation's sole supplier for the active ingredient in a commercially approved cancer therapy such as Lutathera® is a pride point for MU and a responsibility the MURR team takes very seriously."
"Successes like these pull us all together, from researchers to reactor operations to the entire production and supporting teams," said Matt Sanford, MURR interim executive director. "We know we are making a difference in the lives of cancer patients every single day."
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.